Acquired hemophilia due to factor VIII inhibitors in 34 patients (Q44813631)

6 December 2017

1 reference

title

Acquired hemophilia due to factor VIII inhibitors in 34 patients (English)

1 reference

6 December 2017

0 references

Coagulation factor VIII

0 references

1 reference

Bossi P

1

1 reference

6 December 2017

Cabane J

2

1 reference

6 December 2017

Ninet J

3

1 reference

6 December 2017

Dhote R

4

1 reference

6 December 2017

Hanslik T

5

1 reference

6 December 2017

Chosidow O

6

1 reference

6 December 2017

Jouan-Flahault C

7

1 reference

6 December 2017

Horellou MH

8

1 reference

6 December 2017

Leynadier F

9

1 reference

6 December 2017

Liozon E

10

1 reference

6 December 2017

Pouchot J

11

1 reference

6 December 2017

Robin JP

12

1 reference

6 December 2017

Sanderson F

13

1 reference

6 December 2017

Schaeffer A

14

1 reference

6 December 2017

Sicard D

15

1 reference

6 December 2017

Staikowsky F

16

1 reference

6 December 2017

Wechsler B

17

1 reference

6 December 2017

Zittoun R

18

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

American Journal of Medicine

6 December 2017

published in

1 reference

6 December 2017

volume

105

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

400-408

1 reference

Cytotoxic suppression of acquired factor VIII:C inhibitors

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Factor VIII antibodies in rheumatoid arthritis. Effect of cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired haemophilia and rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired factor VIII:C inhibitor in a patient with Sjögren's syndrome: successful treatment with steroid and immunosuppressive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired inhibitors in malignant and nonmalignant disease states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

A hemorrhagic syndrome in Waldenström's macroglobulinemia secondary to immunoadsorption of factor VIII. Recovery after splenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired factor VIII inhibitor preceding chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired factor VIII inhibitor in a patient with mycosis fungoides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired factor VIII:C inhibitor (IgG) and positive direct Coombs' test (IgM) in a patient with lung carcinoma. Clinical course and immunochemical studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Spontaneously acquired anti-factor VIII antibodies: report of a patient with adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired factor VIII inhibitor with squamous cell cancer of the epiglottis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

The use of porcine factor viii in the treatment of patients with acquired hemophilia: The United Kingdom experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Immunochemistry of factor VIII:C inhibitor antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

The Treatment of Patients who have Factor-VIII Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Rationale and evolution of therapy with porcine factor VIII:C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Efficacy of porcine factor VIII in the management of haemophiliacs with inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Anaphylactic reaction to low-molecular-weight porcine factor VIII concentrates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Use of animal AHG concentrates (factor VIII) in the treatment of life-threatening hemorrhage in patients with factor VIII antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

The use of polyelectrolyte-fractionated porcine factor VIII in the treatment of a spontaneously acquired inhibitor to factor VIII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VIII inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

The dental management of patients with spontaneous acquired factor VIII inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Desmopressin therapy in patients with acquired factor VIII inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

DDAVP in acquired hemophilia A: case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

DDAVP in a non-haemophiliac patient with an acquired factor VIII inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Case Report: Successful Use of Antifibrinolytic Therapy in Acquired Factor VIII Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Corticosteroid therapy for acquired F VIII:C inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Syndrome of an acquired inhibitor of factor VIII responsive to cyclophosphamide and prednisone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Successful treatment of acquired hemophilia with oral immunosuppressive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Acquired factor VIII inhibitors in nonhemophilic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease: treatment with intravenous immunoglobulin. A case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Intravenous IgG for patients with spontaneous inhibitor to Factor VIII

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Failure of high-dose i.v. gammaglobulin in the treatment of spontaneously acquired factor VIII inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Plasma exchange in non-haemophiliac patients with inhibitors to factor VIIIC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

Plasmapheresis and Factor VIIIC inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900289-7

10.1016/S0002-9343(98)00289-7

7 January 2021

Identifiers

DOI

1 reference

6 December 2017

1 reference